This article reviews the study 'Examination of Online Direct-to-Consumer Prescription Drug Promotion' (FDA-2011-N-0230), which is designed to test different ways of presenting prescription drug risk and benefit information on branded drug Web sites.
This article is a review of the proposed FDA 'Experimental Study of Direct-to-Consumer Promotion Directed at Adolescents' (FR # FDA-2013-N-1151), which aims to assess how adolescents interpret drug risk in DTC advertising.
This article is a review of FDA's proposed study titled 'Spousal Influence on Consumer Understanding of and Response to Direct-To-Consumer Prescription Drug Advertisements' (FDA-2014-N-1819)
Welcome to Volume 13, Issue #10 (DECEMBER 2014) of Pharma Marketing News.
This article summarized the industry's response to the second FDA social media guidance document regarding correcting and/or responding to misinformation related to a firm's own FDA-approved products when that information is created or disseminated by independent third parties on the Internet or through social media.
This article summarizes the social media accomplishments -- despite bumps in along the way -- that earned the Boehringer Ingelheim (BI) Global Social Media Team the coveted Pharmaguy Social Media Pioneer Award.
This article summarizes the comments from a LinkedIn debate and #mHealthPharma TweetChat and condenses the learnings into one simple formula for creating quality pharma mHealth apps.
Welcome to Volume 13, Issue #9 (OCTOBER 2014) of Pharma Marketing News.
This article asks the question: Can anecdotal 'evidence'/experiences mentioned in patient videos -- even unbranded videos -- cause unnecessary visits to the doctor's office and over prescribing of drugs with serious side effects?
This reviews FDA's recommendations for distributing reprints that convey 'new risk information' for approved drugs.